Regeneron Pharmaceuticals, Inc. [REGN] stock prices are up 1.29% to $1093.14 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The REGN shares have gain 2.72% over the last week, with a monthly amount glided 4.64%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Regeneron Pharmaceuticals, Inc. [NASDAQ: REGN] stock has seen the most recent analyst activity on March 12, 2024, when Bernstein initiated its Outperform rating and assigned the stock a price target of $1125. Previously, RBC Capital Mkts upgraded its rating to Outperform on January 12, 2024, and elevated its price target to $1076. On November 09, 2023, Deutsche Bank initiated with a Hold rating and assigned a price target of $800 on the stock. Raymond James upgraded its rating to a Outperform but stick to its price target of $950 on November 03, 2023. Canaccord Genuity upgraded its rating to a Buy and raised its price target to $992 on August 21, 2023. Oppenheimer reiterated a Perform rating for this stock on August 21, 2023, and upped its price target to $1050. In a note dated June 28, 2023, Canaccord Genuity downgraded an Hold rating on this stock and revised its target price from $953 to $720.
The stock price of Regeneron Pharmaceuticals, Inc. [REGN] has been fluctuating between $726.11 and $1106.16 over the past year. Currently, Wall Street analysts expect the stock to reach $946.05 within the next 12 months. Regeneron Pharmaceuticals, Inc. [NASDAQ: REGN] shares were valued at $1093.14 at the most recent close of the market. An investor can expect a potential drop of -13.46% based on the average REGN price forecast.
Analyzing the REGN fundamentals
The Regeneron Pharmaceuticals, Inc. [NASDAQ:REGN] reported sales of 13.10B for trailing twelve months, representing a drop of -0.54%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at 0.29%, Pretax Profit Margin comes in at 0.34%, and Net Profit Margin reading is 0.32%. To continue investigating profitability, this company’s Return on Assets is posted at 0.12, Equity is 0.16 and Total Capital is 0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1,056.26 points at the first support level, and at 1,019.38 for the second support level. However, for the 1st resistance point, the stock is sitting at 1,115.61, and for the 2nd resistance point, it is at 1,138.08.
Ratios To Look Out For
It’s worth pointing out that Regeneron Pharmaceuticals, Inc. [NASDAQ:REGN]’s Current Ratio is 5.27. On the other hand, the Quick Ratio is 4.51, and the Cash Ratio is 0.55. Considering the valuation of this stock, the price to sales ratio is 9.19, the price to book ratio is 4.46 and price to earnings (TTM) ratio is 32.29.
Transactions by insiders
Recent insider trading involved MARION E MCCOURT, Officer, that happened on Aug 01 ’24 when 1137.0 shares were purchased. Director, Arthur F. Ryan completed a deal on Aug 01 ’24 to buy 300.0 shares. Meanwhile, EVP General Counsel and Secret LAROSA JOSEPH J sold 1866.0 shares on Jul 11 ’24.
